RICH
MCID: RPD005
MIFTS: 38

Rapidly Involuting Congenital Hemangioma (RICH)

Categories: Cardiovascular diseases, Fetal diseases, Rare diseases

Aliases & Classifications for Rapidly Involuting Congenital Hemangioma

MalaCards integrated aliases for Rapidly Involuting Congenital Hemangioma:

Name: Rapidly Involuting Congenital Hemangioma 58
Rich 58

Characteristics:

Orphanet epidemiological data:

58
rapidly involuting congenital hemangioma
Inheritance: Not applicable; Age of onset: Infancy,Neonatal;

Classifications:

Orphanet: 58  
Rare circulatory system diseases
Developmental anomalies during embryogenesis


External Ids:

ICD10 via Orphanet 33 D18.0
UMLS via Orphanet 72 C1275421
Orphanet 58 ORPHA141184

Summaries for Rapidly Involuting Congenital Hemangioma

MalaCards based summary : Rapidly Involuting Congenital Hemangioma, also known as rich, is related to hemangioma and congenital hemangioma. The drugs Hyaluronic acid and Insulin aspart have been mentioned in the context of this disorder. Affiliated tissues include bone, liver and breast, and related phenotypes are telangiectasia of the skin and subcutaneous calcification

Wikipedia : 74 A vascular tumor is a tumor of vascular origin; a soft tissue growth that can be either benign or... more...

Related Diseases for Rapidly Involuting Congenital Hemangioma

Diseases related to Rapidly Involuting Congenital Hemangioma via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 19, show less)
# Related Disease Score Top Affiliating Genes
1 hemangioma 10.8
2 congenital hemangioma 10.8
3 non-involuting congenital hemangioma 10.5
4 arteriovenous malformation 10.2
5 thrombocytopenia 10.2
6 posttransplant acute limbic encephalitis 10.2
7 rare tumor 10.2
8 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.1
9 angioma, tufted 10.1
10 deficiency anemia 10.1
11 telangiectasis 10.1
12 vascular cancer 10.1
13 teratoma 10.1
14 fibrosarcoma 10.1
15 congenital fibrosarcoma 10.1
16 cleft lip 10.1
17 hemangioendothelioma 10.1
18 kaposiform hemangioendothelioma 10.1
19 rare vascular tumor 10.1

Graphical network of the top 20 diseases related to Rapidly Involuting Congenital Hemangioma:



Diseases related to Rapidly Involuting Congenital Hemangioma

Symptoms & Phenotypes for Rapidly Involuting Congenital Hemangioma

Human phenotypes related to Rapidly Involuting Congenital Hemangioma:

58 31 (showing 14, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 telangiectasia of the skin 58 31 frequent (33%) Frequent (79-30%) HP:0100585
2 subcutaneous calcification 58 31 frequent (33%) Frequent (79-30%) HP:0007618
3 midfrontal capillary hemangioma 58 31 frequent (33%) Frequent (79-30%) HP:0007466
4 perineal hemangioma 58 31 frequent (33%) Frequent (79-30%) HP:0031449
5 congestive heart failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0001635
6 thrombocytopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001873
7 peripheral arteriovenous fistula 58 31 occasional (7.5%) Occasional (29-5%) HP:0100784
8 prominent superficial veins 58 31 occasional (7.5%) Occasional (29-5%) HP:0001015
9 avascular necrosis 58 31 very rare (1%) Very rare (<4-1%) HP:0010885
10 lipoatrophy 58 31 very rare (1%) Very rare (<4-1%) HP:0100578
11 hepatic hemangioma 58 31 very rare (1%) Very rare (<4-1%) HP:0031207
12 hemangioma 58 Obligate (100%)
13 visceral hemangioma 58 Occasional (29-5%)
14 tufted angioma 58 Excluded (0%)

Drugs & Therapeutics for Rapidly Involuting Congenital Hemangioma

Drugs for Rapidly Involuting Congenital Hemangioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 930, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
2
Insulin aspart Approved Phase 4 116094-23-6 16132418
3
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
4
Asenapine Approved Phase 4 65576-45-6, 85650-56-2 3001386
5
Lactulose Approved Phase 4 4618-18-2 11333
6
Insulin glulisine Approved Phase 4 207748-29-6
7
Insulin lispro Approved Phase 4 133107-64-9
8
Linagliptin Approved Phase 4 668270-12-0 10096344
9
Cimetidine Approved, Investigational Phase 4 51481-61-9 2756
10
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
11
leucovorin Approved Phase 4 58-05-9 6006 143
12
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
13
Simvastatin Approved Phase 4 79902-63-9 54454
14
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
15
Magnesium citrate Approved Phase 4 3344-18-1
16
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
17
Primaquine Approved Phase 4 90-34-6 4908
18
Artesunate Approved, Investigational Phase 4 88495-63-0 6917864 5464098
19 Artichoke Approved Phase 4
20
Dimenhydrinate Approved Phase 4 523-87-5 441281
21
Ezetimibe Approved Phase 4 163222-33-1 150311
22
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
23
Metronidazole Approved Phase 4 443-48-1 4173
24
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
25
Pentazocine Approved, Vet_approved Phase 4 359-83-1 441278
26
Palonosetron Approved, Investigational Phase 4 135729-56-5, 119904-90-4 148211
27
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
28
Lixisenatide Approved Phase 4 320367-13-3
29
Allopurinol Approved Phase 4 315-30-0 2094
30
Ribavirin Approved Phase 4 36791-04-5 37542
31
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
32
Histamine Approved, Investigational Phase 4 51-45-6 774
33
Amodiaquine Approved, Investigational Phase 4 86-42-0 2165
34
Ferrous succinate Approved Phase 4 10030-90-7
35
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
36
Xylometazoline Approved, Investigational Phase 4 526-36-3 5709
37
Glimepiride Approved Phase 4 93479-97-1 3476
38
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
39
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
40
Atorvastatin Approved Phase 4 134523-00-5 60823
41
Lenograstim Approved, Investigational Phase 4 135968-09-1
42
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
43
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
44
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
45
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
46
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
47
Probucol Approved, Investigational Phase 4 23288-49-5 4912
48
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
49
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
50
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
51
Clarithromycin Approved Phase 4 81103-11-9 84029
52
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
53
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
54
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
55
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
56
Ofloxacin Approved Phase 4 82419-36-1 4583
57
Citalopram Approved Phase 4 59729-33-8 2771
58
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
59
Abacavir Approved, Investigational Phase 4 136470-78-5 441300 65140
60
Febuxostat Approved Phase 4 144060-53-7 134018
61
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
62
Glucagon Approved Phase 4 16941-32-5
63
Liraglutide Approved Phase 4 204656-20-2 44147092
64
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
65
tannic acid Approved Phase 4 1401-55-4
66
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
67
Kinetin Approved Phase 4 525-79-1 3830
68
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
69
Ticagrelor Approved Phase 4 274693-27-5 9871419
70
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
71
Fenofibrate Approved Phase 4 49562-28-9 3339
72
Altretamine Approved Phase 4 645-05-6 2123
73
Adenosine Approved, Investigational Phase 4 58-61-7 60961
74
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
75
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
76 Garlic Approved, Nutraceutical Phase 4 8008-99-9
77
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
78
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
79
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
80
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
81
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
82
Valine Approved, Nutraceutical Phase 4 72-18-4 6287
83
Methionine Approved, Nutraceutical Phase 4 63-68-3 6137
84
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
85 Flurbiprofen axetil Investigational Phase 4 91503-79-6
86
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 5323714 3435